Nana Baidoo , Aiden Shaver , Brooke Ginson , Julia Castellani , Thomas Lapointe , Michael Wolter , Francesco Leri
{"title":"Memory enhancement by unconditioned and conditioned heroin withdrawal: Role of corticotropin-releasing factor in the central amygdala","authors":"Nana Baidoo , Aiden Shaver , Brooke Ginson , Julia Castellani , Thomas Lapointe , Michael Wolter , Francesco Leri","doi":"10.1016/j.neuropharm.2025.110341","DOIUrl":null,"url":null,"abstract":"<div><div>To test the hypothesis that unconditioned and conditioned opioid withdrawal enhance memory consolidation through shared neurobiological mechanisms, the current study focused on the central amygdala (CeA) and local corticotropin-releasing factor (CRF) neurotransmission. In the unconditioned withdrawal experiments, male Sprague-Dawley rats were implanted with subcutaneous osmotic mini-pumps releasing 3.5 mg/kg/day heroin (or sham surgery) and injected with 3 mg/kg naloxone (NLX) to precipitate withdrawal. In the conditioned withdrawal experiments, rats injected with heroin (2 mg/kg x 2 injections) received 3 mg/kg NLX immediately prior to confinement to one compartment (CS+) of a place conditioning apparatus, or vehicle prior to confinement in the alternative compartment (CS-). Using immunohistochemistry, it was established that both precipitated withdrawal and confinement to the withdrawal-paired CS + compartment elevated c-Fos expression within the CeA. More importantly, using the post-training approach to target consolidation of object memory, it was found that intra-CeA infusions of the CRF1 receptor antagonist ANT (0.2–2 μg/inf) blocked the memory-enhancing effects of both precipitated withdrawal and exposure to the withdrawal-paired CS + compartment. These findings indicate that pharmacological and conditioned opioid withdrawal influence memory consolidation through a common CRF-mediated mechanism within the CeA.</div></div>","PeriodicalId":19139,"journal":{"name":"Neuropharmacology","volume":"269 ","pages":"Article 110341"},"PeriodicalIF":4.6000,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0028390825000474","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
To test the hypothesis that unconditioned and conditioned opioid withdrawal enhance memory consolidation through shared neurobiological mechanisms, the current study focused on the central amygdala (CeA) and local corticotropin-releasing factor (CRF) neurotransmission. In the unconditioned withdrawal experiments, male Sprague-Dawley rats were implanted with subcutaneous osmotic mini-pumps releasing 3.5 mg/kg/day heroin (or sham surgery) and injected with 3 mg/kg naloxone (NLX) to precipitate withdrawal. In the conditioned withdrawal experiments, rats injected with heroin (2 mg/kg x 2 injections) received 3 mg/kg NLX immediately prior to confinement to one compartment (CS+) of a place conditioning apparatus, or vehicle prior to confinement in the alternative compartment (CS-). Using immunohistochemistry, it was established that both precipitated withdrawal and confinement to the withdrawal-paired CS + compartment elevated c-Fos expression within the CeA. More importantly, using the post-training approach to target consolidation of object memory, it was found that intra-CeA infusions of the CRF1 receptor antagonist ANT (0.2–2 μg/inf) blocked the memory-enhancing effects of both precipitated withdrawal and exposure to the withdrawal-paired CS + compartment. These findings indicate that pharmacological and conditioned opioid withdrawal influence memory consolidation through a common CRF-mediated mechanism within the CeA.
期刊介绍:
Neuropharmacology publishes high quality, original research and review articles within the discipline of neuroscience, especially articles with a neuropharmacological component. However, papers within any area of neuroscience will be considered. The journal does not usually accept clinical research, although preclinical neuropharmacological studies in humans may be considered. The journal only considers submissions in which the chemical structures and compositions of experimental agents are readily available in the literature or disclosed by the authors in the submitted manuscript. Only in exceptional circumstances will natural products be considered, and then only if the preparation is well defined by scientific means. Neuropharmacology publishes articles of any length (original research and reviews).